Videos

An overview of treatment strategies and multimodality care essential to the management of psoriatic arthritis.

Roy Fleishmann, MD, discusses his Rheumatology Winter Clinical Symposium presentation, “SLE Update: Novel treatments, and how we assess them.”

Chair of the ACR COVID-19 Vaccine Clinical Guidance Task Force, Jeffrey Curtis, discusses the newest vaccine recommendations amid the Omicron variant.

Vibeke Strand explains that secukinumab improves psoriatic arthritis in patients regardless of their treatment history.

Shared insight on the role that nurse practitioners and advanced practice care providers have in the management of patients with psoriatic arthritis.

Experts review the pathophysiology of psoriatic arthritis and share their perspective on how it can impact patients and caregivers.

Rheumatology Network interviewed Terence Rooney, MD, to discuss the findings of a Network Meta-Analysis that examined the efficacy of guselkumab (TREMFYA) for skin clearance and joint improvements in patients with psoriatic arthritis.

A panel of experts discuss the presentation of psoriatic arthritis and domains of disease.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, review the pathophysiology of psoriatic arthritis.

Mary Wheatley, IOM, CAE, discusses the National Scleroderma Foundation, its recent name change, and the importance of raising awareness of this rare rheumatic condition.

Chengappa Kavadichanda, MD, discusses his study, “Short term outcomes of COVID-19 in lupus: Propensity score matched analysis from a nationwide multi-centric research network.”

W. Benjamin Nowell, PhD, Director, Patient-Centered Research, CreakyJoints, discusses his study, "Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower® Registry.”

Ana-Maria Orbai, MD, MHS, leads the discussion on a real-world case scenario of a 57-year-old man who presents with severe plaque psoriasis and arthritis and shares clinical impressions as well as therapeutic goals for the patient.

Sheetal Desai, MD, leads the discussion on a real-world case scenario of a 26-year-old woman with polyarticular symmetric psoriatic arthritis and shares her approach to treatment.

Leonard H. Calabrese, DO, leads the discussion on a real-world case-based scenario of a 31-year-old woman with psoriatic arthritis and shares clinical impressions.

Ana-Maria Orbai, MD, MHS; Anthony M. Turkiewicz, MD; Leonard H. Calabrese, DO; and Sheetal Desai, MD, comment on the appropriate circumstances to switch therapies for the management of psoriatic arthritis.

Ana-Maria Orbai, MD, MHS, comments on the safety and efficacy of TNF-alpha inhibitors for the management of psoriatic arthritis and Anthony M. Turkiewicz, MD, reviews the phase 3 FUTURE trials.

James Woody, MD, PhD, explains the key findings of the Phase 2b clinical trial, “Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD).”

Roy Fleischmann, MD, explores the successful results of the novel IL-6 inhibitor, olokizumab, from 2 randomized clinical trials of the phase 3 global research program CREDO.

Sheetal Desai, MD, reviews the MOAs of currently available biologics for the management of psoriatic arthritis.

Leonard H. Calabrese, DO, shares insight on goals of therapy and factors that guide treatment selection for patients with psoriatic arthritis.

Stuart Kassan, MD, discusses Rheumatology Research Foundation's recent patient webinar, "Just Diagnosed: Now What?”

Anthony M. Turkiewicz, MD, leads the discussion on diagnosing psoriatic arthritis (PsA), including differentiating PsA from axial spondyloarthritis, and comments on the role of CASPAR criteria in clinical practice.

Sheetal Desai, MD, leads the discussion on the typical presentation of psoriatic arthritis, common comorbidities associated with the disease, and the importance of an early and accurate diagnosis.

Louis Bessette, MD, MSc, explains the impact of early pain improvement on patient-reported outcomes in patients with psoriatic arthritis.

Benjamin Terrier, MD, PhD, discusses his study and ACR presentation, “Rituximab versus Conventional Therapeutic Strategy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis: A Double-blind, Randomized, Controlled Trial.”

Paul R. Fortin, MD, MPH, FRCPC, discusses the impact of the COVID-19 vaccine in immunosuppressed adults and those with autoimmune diseases.

Leonard H. Calabrese, DO; Sheetal Desai, MD; and Ana-Maria Orbai, MD, MHS, discuss the impact of psoriatic arthritis on a patient’s quality of life [QoL] and describe tools for measuring QoL.

Leonard H. Calabrese, DO, provides insight on the pathophysiology of psoriatic arthritis [PsA].

Courtney Wells, PhD, MPH, MSW, discusses the impact of the pandemic on the quality of life of patients with rheumatic conditions, with an emphasis on perceived risk and decision making.